Anti-complement strategies in experimental sepsis

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 9, 2003, Pages 601-603

  Ward, Peter A ^a   Riedemann, Niels C ^a   Guo, Ren Feng ^a   Huber Lang, Markus ^b   Sarma, J Vidya ^a   Zetoune, Firas S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; COMPLEMENT; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; HYDROGEN PEROXIDE; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; PROTEIN ANTIBODY; RECEPTOR ANTIBODY;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CECUM; CHEMOTAXIS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DISEASE COURSE; ENZYME ACTIVATION; EXPERIMENTAL ANIMAL; IMMUNE RESPONSE; LEUKOCYTE FUNCTION; LIGATION; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PUNCTURE; RAT; RESPIRATORY BURST; RODENT; SEPSIS; SURVIVAL RATE; THYMOCYTE; THYMUS; UPREGULATION;

ANIMALS; CHEMOTAXIS; COMPLEMENT C5A; DISEASE MODELS, ANIMAL; HUMANS; MICE; PHAGOCYTOSIS; RATS; RESPIRATORY BURST; SEPSIS; UP-REGULATION;

EID: 0242288515     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540310015674     Document Type: Article

References (13)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54.
2. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003; 9: 517-24.
3. Huber-Lang M, Sarma JV, McGuire SR, Lu KT, Padgaonkar V, Younkin EM, et al. Structure-function relationships of human C5a and C5aR. J Immunol 2003; 170: 6115-24.
4. Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, Guo RF, et al. Role of C5a in multiorgan failure during sepsis. J Immunol 2001; 66: 1193-9.
5. Huber-Lang MS, Younkin EM, Sarma JV, McGuire SR, Lu KT, Guo RF, et al. Complement-induced impairment of innate immunity during sepsis. J Immunol 2002; 169: 3223-31.
6. Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, et al. Protective effects of C5a blockade in sepsis. Nat Med 1999; 5: 788-92.
7. Guo RF, Huber-Lang M, Wang X, Sarma V, Padgaonkar A, Craig RA, et al. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest 2000; 106: 1271-80.
8. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 1999; 96: 14541-6.
9. Riedemann NC, Guo RF, Neff TA, Laudes IJ, Keller KA, Sarma VJ, et al. Increased C5a receptor expression in sepsis. J Clin Invest 2002; 110: 101-8.
10. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV, et al. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 2003; 170: 503-7.
11. Huber-Lang MS, Riedeman NC, Sarma JV, Younkin EM, McGuire SR, Laudes U, et al. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 2002; 16: 1567-74.
12. Laudes IJ, Chu JC, Sikranth S, Huber-Lang M, Guo RF, Riedemann N, et al. Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 2002; 160: 1867-75.
13. Furebring M, Hakansson LD, Venge P, Nilsson B, Sjolin J. Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Crit Care 2002; 6: 363-70.